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In a recent Letter to the Editor [1], Talebi Bezmin Abadi
commented on the paper by Arama et al. [2], in which the
authors concluded that a 2-week regimen (Proton Pump
inhibitor, plus Clarithromycin plus Amoxicillin) is preferable
to a 7-day regimen as first-line therapy forHelicobacter pylori
(H. pylori) infection. In his Letter, Talebi Bezmin Abadi con-
cluded that “Certainly, preantibiotic susceptibility tests are
inevitable approach in H. pylori therapy.” Although we agree
with all comments, we found the conclusion inappropriate.
The 4th Maastricht/Florence Consensus Conference rec-
ommended abandoning clarithromycin in empirical treat-
ment when the prevalence of resistance is higher than 15–20%
[3].
In the paper by Arama et al. [2], the overall eradica-
tion rate observed was 70.5%: the number of patients who
responded to treatment was significantly greater in the 14-day
treatment (84.6%) group compared to patients who received
the 7-day treatment (42.3%) (𝑝 < 0.001).
An acceptable eradication rate is differently defined in
literature (>75% [4], ≥ 90–95% [5]) and the clinicians should
“use only what works locally” ignoring consensus statements
and society guidelines if these are not consistent with local
treatment results [6]. Moreover, antibiotic resistance should
be considered as a dynamic concept, since its prevalence can
change not only among different countries, but also between
two different periods in the same area [7].
A culture-based approach, in clinical practice, is often
unfeasible and its costmay be hard to afford [8]. Furthermore,
the whole process needs a standard of quality (in terms of
bothmaterials used for culture and skill of the microbiologist
to grow H. pylori) that cannot be assured everywhere [7].
Probably, the cost-effectiveness of the culture-based approach
may change depending on host-related factors (bleeding, use
of certain drugs) and methodology-related factors (number
of gastric biopsies, conditions of transport, and laboratory
characteristics) [7]. These factors may be favorable in some
settings compared to others.
Hence, in the year 2016 a culture-guided treatment must
be taken into account only in settings with experience in this
issue and after failure of previous regimens.
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